 | | | | |
| |  | |  | | |
| |  |
| PRIME NEWS |  |
|
 |
|
|
Novartis has received Japanese drug regulator's nod to launch three medicines for Diabetes, high BP and kidney cancer
|
|
|
|
|
|
|
|
|
Omnicare Clinical Research and Clinimetrics Research Associates, both clinical research organizations (CROs) wholly owned by Omnicare, announced the launch of a joint global safety surveillance and pharmacovigilance solution
|
|
|
|
|
|
|
 | | |
The latest pharmaceutical technology news, trends and analysis, pharma business and investment opportunities, pharmaceutical technology breakthroughs, launch and review of pharma, biopharma & pharmaceutical products, features, event listings and job postings.
| | | | |  | |  | | |
|
|
 |
|
 |
|
|
|
 |
NEWS |
 |
|
|
|
|
|
SIRO forms alliance with Korean CRO DreamCIS
|
|
| SIRO Clinpharm, a CRO with presence in India, Western and Central Eastern Europe, and the US has announced its alliance with DreamCIS, a leading CRO based in Seoul, South Korea |
|
|
|
|
|
|
 |
|
 |
|
|
|
|
|
|
|
|
|
|
FEATURES |
|
|
|
|
Big pharma slashes R&D budget: A reason of concern?
|
|
| Pharma companies have announced a major reduction in their R&D budgets in the coming years. What repercussions will it create on the pharma industry? Increasing R&D productivity was the unanimous reason given out by the heads of these companies |
|
|
|
|
|
All Eyes on Chinese healthcare market
|
|
| The overall compound annual growth rate of the pharmaceutical market (2009-2013), for its part, is projected to be 24%, with the market reaching an estimated $73 billion by 2013 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PEOPLE |
|
|
|
|
GSK Japan gets new President
|
|
| GlaxoSmithKline has appointed Mr Philippe Fauchet as the President of GSK Japan. Mr Fauchet joins GSK from Sanofi Aventis where he was Senior Vice President, Business Development |
|
|
|
|
|
Daniel Vasella to leave Novartis, Joe Jimenez new CEO
|
|
| After 14 years as the CEO, Daniel Vasella is stepping down as Novartis CEO. He is being replaced by Joe Jimenez, the current head of Novartis' pharma division. Dr. Daniel Vasella served 14 years as CEO and 11 years as Chairman and CEO |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
POLICIES |
|
|
|
|
FDA approves new indication for CRESTOR
|
|
| AstraZeneca announced that the US Food FDA has approved CRESTOR (rosuvastatin calcium) to reduce the risk of stroke, myocardial infarction and arterial revascularization procedures in individuals without clinically evident coronary heart disease |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PRODUCTS |
|
|
|
|
Ranbaxy launches Lulifin in India
|
|
| Ranbaxy Laboratories, India's largest pharmaceutical company by revenues, has launched a New Chemical Entity (NCE), Lulifin in the Indian Dermatology market |
|
|
|
|
|
bioMerieux selects Brainware to automate accounts payable
|
|
| Brainware, an innovative provider of intelligent data capture and enterprise search solutions, announced that bioMerieux, a global biotechnology company, has selected its Brainware Distiller solution to automate its accounts payable process |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|  | |  | | | | |  | |  |
|
|
|
| | | | | | | | |
